Xi'an Faithful BioTech Co., Ltd. is selling Elamipretide Raw Powder. Please feel free to contact us if you have any purchase needs.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
I. Introduction: Definition and Core Value of Raw Elamipretide
Raw Elamipretide, or raw material-grade elamipretide, is a synthetic tetrapeptide compound with CAS number 736992-21-5. Its core characteristic is its mitochondrial-targeting bioactivity, enabling it to penetrate cells and locate within the inner mitochondrial membrane. By regulating mitochondrial function, it exerts a cytoprotective effect, making it a crucial raw material for current research in the treatment of mitochondrial diseases. As a raw material, Raw Elamipretide forms the core foundation for subsequent formulation development, clinical trials, and basic research; its purity, stability, and other quality indicators directly determine the reliability and efficacy of downstream applications.
The discovery of Elamipretide was accidental, involving a functional small molecule peptide. Unlike traditional antioxidant or anti-inflammatory products, it innovatively targets mitochondria, providing a novel approach to addressing age-related diseases, cardiovascular diseases, and neurodegenerative diseases caused by mitochondrial dysfunction. Raw Elamipretide, as the original form of this compound, has been the subject of extensive research, encompassing chemical synthesis, quality control, and mechanism of action analysis, laying a solid foundation for its clinical translation and application.
II. Chemical and Physical Properties of Raw Elamipretide
2.1 Chemical Structure and Molecular Characteristics
Raw Elamipretide is a synthetic polypeptide composed of four amino acids, with the chemical formula C₃₂H₄₉N₉O₅ and a molecular weight of 639.8 g/mol. This unique amino acid composition endows it with alternating cation-aromatic motifs, a structural feature crucial for its ability to penetrate cell membranes and specifically bind to the inner mitochondrial membrane.
2.2 Physical Properties and Morphological Characteristics
Raw-grade Elamipretide typically appears as a sterile, filtered, white, lyophilized powder, odorless and tasteless. Regarding solubility, this substance is readily soluble in sterile ultrapure water (18 MΩ·cm). A reconstitution concentration of at least 100 μg/ml is recommended, after which it can be further diluted in other aqueous solutions. High purity is required; analysis using reversed-phase high-performance liquid chromatography (RP-HPLC) typically yields a purity greater than 97.0%. High-purity raw materials ensure the accuracy of subsequent research and formulation development. Furthermore, Raw Elamipretide is hygroscopic and must be stored in a dry environment to prevent structural damage.
Send your Inquiry for more details, Click email：sales4@faithfulbio.com
III. Preparation Process of Raw Elamipretide
3.1 Main Synthetic Methods
Currently, the preparation of Raw Elamipretide mainly employs chemical synthesis methods, among which solid-phase peptide synthesis (SPPS) is one of the most commonly used methods. This method uses resin as a solid-phase carrier, starting from the C-terminal amino acid, and sequentially adding amino acid residues one by one through a cyclic reaction of "deprotection-activation-coupling". During the synthesis process, the reaction temperature, time, and reagent ratios must be strictly controlled to ensure the correct linkage of amino acids and avoid mismatches or deletions. After synthesis, the peptide is cleaved from the resin using specific reagents, and then purified by high-performance liquid chromatography (HPLC) to finally obtain a high-purity Raw Elamipretide product.
In addition to solid-phase synthesis, some studies have also used biosynthesis methods, that is, using genetic engineering technology, inserting the gene sequence encoding Elamipretide into an expression vector, and then introducing it into host cells such as E. coli, where the fusion protein is synthesized through transcription and translation. Subsequent steps, including cell disruption, fusion protein separation, and enzymatic cleavage to release the target peptide, resulted in the purified Raw Elamipretide. Furthermore, the latest patented technology discloses a large-scale synthesis method based on N-carboxylic anhydride (NCA)-modified amino acid residues. This method significantly improves synthesis efficiency and product purity, overcoming the technical challenges of traditional synthetic routes in industrial scale-up.
3.2 Key Control Points in the Synthesis Process
In the synthesis process of Raw Elamipretide, several steps directly affect product quality. First, the purity of the amino acid raw materials must be controlled. High-purity amino acid reagents must be selected, especially for the non-natural amino acid 2',6'-dimethyltyrosine, as insufficient purity leads to increased impurities in the final product. Second, the efficiency of the coupling reaction needs to be optimized. The type and amount of activator must be optimized to ensure complete amide bond formation between amino acids and reduce incomplete coupling impurities. In addition, the cleavage and purification steps are crucial for improving product purity. By optimizing the chromatographic conditions of HPLC purification, byproducts, unreacted raw materials, and degradation products generated during synthesis can be effectively removed, ensuring that the final product meets purity requirements.
IV. Mechanism of Action of Raw Elamipretide
4.1 Core Mechanism: Specific Interaction with Cardiolipin
The core bioactivity of raw elamipretide lies in its targeted binding ability to the inner mitochondrial membrane, which depends on cardiolipin (CL), an anionic phospholipid specific to the inner mitochondrial membrane. Cardiolipin plays a crucial role in mitochondrial energy metabolism, membrane stability, and apoptosis; structural or functional abnormalities can directly lead to mitochondrial dysfunction. Nuclear magnetic resonance (NMR) studies have shown that elamipretide binds to the inner mitochondrial membrane in two states: "peptide proximity" and "peptide intercalation." Through non-specific cationic charge interactions and specific chemical interactions, it reduces the negative charge density of the cardiolipin-rich bilayer membrane.
This interaction not only reduces the oxidative modification of cardiolipin acyl chains by cytochrome c (CytC), but also alters the physical properties of the mitochondrial membrane, such as increasing cardiolipin self-association, reducing lipid lateral diffusion rate, and enhancing lateral stacking capacity, while maintaining the layered bilayer structure of the membrane, thereby maintaining the integrity and functional stability of the inner mitochondrial membrane. Based on this core role, Mitchell et al. proposed three therapeutic mechanism models: first, regulating the distribution of divalent cations such as Ca²⁺ to improve membrane properties; second, reducing the toxic interaction between basic proteins and cardiolipin-rich membranes to avoid lipid peroxidation; and third, optimizing the environment for the action of mitochondrial function-related proteins by altering the local curvature of the membrane.
4.2 Regulatory Effects on Mitochondrial Function
Raw Elamipretide, by binding to cardiolipin, further regulates the function of various inner mitochondrial membrane proteins, thereby improving mitochondrial energy metabolism. Studies have found that Elamipretide interacts with the cytochrome c oxidase (CIV) subunit NDUA4, promoting CIV integration into the electron transport chain (ETS) supercomplex, improving the maximum uncoupling respiratory efficiency of cardiac mitochondria in aged mice, and reducing hydrogen peroxide (H₂O₂) production. Simultaneously, it can directly bind to adenosine diphosphate (ADP)/ATP translocase (ANT)1, cross-linking ANT1 with its matrix surface through two lysine residues, increasing ANT1's sensitivity to ADP and transport efficiency, reducing proton leakage, stabilizing mitochondrial membrane potential, and thus enhancing ATP production.
Furthermore, raw Elamipretide also improves the assembly and stability of the electron transport chain supercomplex. In normal mitochondria, respiratory complexes I-IV assemble into a supercomplex to improve electron transport efficiency, while in mitochondrial diseases (such as Barth syndrome), these supercomplexes are unstable and their numbers are reduced. Elamipretide can stabilize cardiolipin structure, promote the assembly of supercomplexes, enhance electron transport efficiency, and stabilize ATP synthase (including ANT and ATP synthase), thus comprehensively restoring mitochondrial energy metabolism function. In aged mouse models, Elamipretide has also been shown to interact with prohibitin 2, improving mitochondrial turnover and nerve damage by inhibiting the cGAS-STING pathway and M1 microglia polarization, further expanding the dimensions of its mitochondrial protective mechanism.
V. Application Areas and Research Progress of Raw Elamipretide
5.1 Cardiovascular Diseases
Mitochondrial dysfunction is a crucial pathological basis for cardiovascular diseases such as cardiomyopathy and heart failure. Raw Elamipretide, due to its mitochondrial protective effects, has shown significant application potential in this field. In a fibroblast model of dilated cardiomyopathy with ataxia syndrome (DCMA), Elamipretide reversed mitochondrial fragmentation and excessive reactive oxygen species (ROS) generation, maintaining the ultrastructure of the mitochondrial membrane. In an aged mouse model of left ventricular diastolic dysfunction, after 8 weeks of Elamipretide treatment, the mice's left ventricular diastolic function returned to normal, exercise tolerance improved, cardiac hypertrophy decreased, and mitochondrial proton leakage and ROS generation returned to normal levels.
5.2 Rare Disease Treatment Research
Barth syndrome is an X-linked recessive rare disease caused by mutations in the TAFAZZIN gene, leading to a deficiency in cardiolipin synthesis and subsequent mitochondrial dysfunction. The main manifestations include dilated cardiomyopathy, skeletal muscle weakness, and neutropenia, with a high childhood mortality rate. The protective effect of raw elamipretide against cardiolipin has made it an important research direction for the treatment of Barth syndrome. In a TAFAZZIN gene knockdown mouse model, elamipretide significantly improved mitochondrial respiration, promoted the assembly of the electron transport chain supercomplex, improved cardiac function and skeletal muscle weakness symptoms, and improved the quality of life of mice. Related clinical studies have also shown that elamipretide can improve cardiac function indicators and hematological parameters in patients with Barth syndrome, representing a breakthrough in the treatment of this rare disease.
5.3 Research on Neurodegenerative Diseases and Aging
Mitochondrial function decline is a common feature of aging and neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease). The mitochondrial protective effects of raw elamipretide have made it a focus of research in this field. In aged mouse models, elamipretide can improve mitochondrial turnover, inhibit neuroinflammatory responses, and reduce nerve damage by interacting with prohibitin 2, thus playing a positive role in maintaining cognitive function. Furthermore, in age-related skeletal muscle function decline models, elamipretide can improve skeletal muscle energy metabolism efficiency, enhance fatigue resistance and exercise endurance. In a randomized, placebo-controlled trial in healthy elderly individuals, a single dose of elamipretide significantly increased the maximum ATP production in skeletal muscle, demonstrating its potential for anti-aging in humans.
5.4 Ophthalmic Diseases
Dry age-related macular degeneration (DAMD) is one of the leading causes of blindness in the elderly. Its pathological basis is mitochondrial dysfunction in retinal pigment epithelial cells (RPE), leading to ROS accumulation and RPE cell death, which in turn damages photoreceptor cells. Raw elamipretide can protect mitochondrial function in RPE cells, reduce ROS production, and delay RPE cell apoptosis, thereby halting the progression of dry AMD. Currently, clinical trials of elamipretide for the treatment of dry AMD are underway, providing new insights into the treatment of this disease.
VI. Research Prospects and Challenges of Raw Elamipretide
6.1 Research and Application Prospects
As a functional peptide raw material targeting mitochondria, the application prospects of raw elamipretide are constantly expanding. In the field of clinical treatment, in addition to the existing clinical trials for indications such as cardiovascular diseases, rare diseases, and ophthalmic diseases, it may be expanded to more diseases related to mitochondrial dysfunction, such as diabetic complications, chronic kidney disease, and motor neuron disease. In the scientific research field, it will continue to serve as an important tool for studying the regulatory mechanisms of mitochondrial function, helping scientists to delve deeper into the link between mitochondria and the development of diseases. Furthermore, with the optimization of the synthesis process, the industrial production capacity of Raw Elamipretide will be further enhanced, ensuring its widespread application.
6.2 Challenges Faced
Although Raw Elamipretide demonstrates great application potential, it still faces several challenges. First, long-term safety data is insufficient. Although short-term clinical trials have not found significant toxic side effects, the potential impact of long-term use on the human body still needs further verification. In addition, the high synthesis cost is also a factor limiting its widespread application, requiring further optimization of the synthesis process to reduce production costs. Finally, the therapeutic dosage and course of treatment for different diseases are not yet fully clear and need to be explored and determined through more clinical trials.
Conclusion
Raw elamipretide, a novel peptide targeting mitochondria, has demonstrated significant value in the treatment of various diseases related to mitochondrial dysfunction due to its unique mechanism of action and remarkable cytoprotective effects. From its chemical properties and preparation process to its mechanism of action and application areas, research on raw elamipretide has formed a relatively complete system, laying a solid foundation for its clinical translation and scientific research application. Although challenges remain, such as safety validation, administration optimization, and cost control, with continuous research and technological advancements, it is believed that raw elamipretide will play an even more important role in the future of biomedicine, bringing new hope for the treatment of more diseases.
As a provider of premium Elamipretide CAS 736992-21-5, Xi'an Faithful BioTech Co., Ltd. leverages state-of-the-art production technology and rigorous quality assurance to meet international pharmaceutical requirements. Our dedication to superior quality, cost-effective pricing, and tailored technical support has made us the preferred collaborator for healthcare professionals and researchers worldwide. To obtain detailed specifications and application guidance for our Elamipretide Powder, contact our technical team at sales4@faithfulbio.com and explore how our offerings can enhance your product formulations.